Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiac Lipid Metabolism: Cells, Metabolites, and Rhythms.

Circulation research·2026

Same author

The N-terminus of apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells.

The Journal of clinical investigation·2026

Same author

Alveolar type 2 cell LRP1 is needed for surfactant phospholipid metabolism and pulmonary function in mice.

Journal of lipid research·2026

Same author

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial.

Nature medicine·2026

Same author

A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes.

Circulation research·2026

Same author

Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice.

Nature communications·2026

Same journal

Navigating Adrenal Disease: A Comprehensive, Practical Guide for the Clinician.

Endocrinology and metabolism clinics of North America·2026

Same journal

Adrenal Disorders in Pregnancy.

Endocrinology and metabolism clinics of North America·2026

Same journal

Diagnosis and Management of Adrenocortical Carcinoma.

Endocrinology and metabolism clinics of North America·2026

Same journal

Pheochromocytomas and Paragangliomas.

Endocrinology and metabolism clinics of North America·2026

Same journal

Hereditary Conditions Associated with Adrenocortical Carcinoma, Pheochromocytoma, and Other Adrenal Tumors: Genetic Testing and Management Recommendations.

Endocrinology and metabolism clinics of North America·2026

Same journal

Primary Bilateral Macronodular Adrenal Hyperplasia.

Endocrinology and metabolism clinics of North America·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Hypertriglyceridemia: impact and treatment.

Ira J Goldberg¹

¹Division of Preventive Medicine and Nutrition, Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY10032, USA. ijg3@columbia.edu

Endocrinology and Metabolism Clinics of North America

|February 17, 2009

Summary

This summary is machine-generated.

Treating high low-density lipoprotein cholesterol is standard. However, triglyceride lowering is only clearly beneficial for preventing pancreatitis in severe hyperchylomicronemia, with cardiovascular benefits unproven.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Experiment Videos

Last Updated: Jun 25, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiology
Metabolic Disorders
Lipid Metabolism

Background:

Elevated low-density lipoprotein cholesterol (LDL-C) treatment is well-established with clear outcome data.
Information regarding hypertriglyceridemia management and its cardiovascular implications is less definitive.
Severe hyperchylomicronemia management focuses on pancreatitis risk reduction through triglyceride lowering.

Purpose of the Study:

To evaluate the current understanding and clinical practice surrounding hypertriglyceridemia treatment.
To examine the evidence linking triglyceride levels to cardiovascular disease (CVD).
To assess the proven benefits of triglyceride-lowering medications in reducing cardiovascular events.

Main Methods:

Review of existing medical literature and clinical guidelines on lipid management.
Analysis of studies investigating the relationship between triglycerides and cardiovascular risk.
Examination of data on the efficacy of triglyceride-lowering therapies for CVD prevention.

Main Results:

The cardiovascular benefits of reducing triglycerides and using related medications remain unproved.
Triglyceride lowering is clearly indicated for severe hyperchylomicronemia to prevent pancreatitis.
Despite unclear CVD benefits, reducing triglyceride-rich lipoproteins is common practice.

Conclusions:

While LDL-C treatment is standard, hypertriglyceridemia management requires further research regarding cardiovascular outcomes.
Current evidence primarily supports triglyceride lowering for pancreatitis prevention in specific severe cases.
The widespread practice of reducing triglyceride-rich lipoproteins may not be fully supported by conclusive cardiovascular outcome data.